Hopen Therapeutics is a private investment and management firm focused on helping early- to
mid-stage life science developments achieve commercial success. We focus on identifying promising
healthcare innovations, whether the concept is a drug, medical device, or other healthcare
product. We then build value by accelerating the time to market.
As a privately held company, Hopen is free to choose the investments and partners that offer
the best potential for market success. We are not bound by a specific disease indication, market
size, or geographic area.
Our business model is flexible, allowing us to enter into a variety of partner relationships. In
pharmaceuticals, for example, we target what the industry calls the “valley of death” – the funding
gap between discovery and later-stage development. Then we typically form a company to develop
the therapy for clinical use worldwide.
Hopen assumes financial and managerial responsibilities for each selected investment. To carry out
these opportunities, we work with experts in a variety of independent research, biotech, pharmaceutical,
manufacturing, distribution, and marketing organizations. This resource network gives us access to specialized
expertise whenever and wherever we need it. To bring products to market, we form strategic alliances with
companies that can ensure market success and growth.
|
|
|
Our mission is to efficiently bring life science innovations to market worldwide through our industry expertise and our flexible resource network.
|
|
|
|
Hopen Therapeutics was founded in Grand Rapids, Michigan, in 2005, by a team of professionals who
shared a vision for streamlining the life science product development pathway. Taking advantage of converging
market dynamics, Hopen’s founders created a way to get product concepts to market faster and more
cost effectively by serving as a conduit to the necessary resources. These market dynamics were:
- Scientific resource availability. A significant number of pharmaceutical experts
became available as a result of widespread industry downsizing in Michigan. This allowed Hopen to
bring together a unique network of experts to help expedite the development of therapeutic breakthroughs.
- Funding availability. The State of Michigan and private donors began investing in the life science sector,
devoting more than $2 billion to encourage medical discoveries.
- Pipeline pressure. The pharmaceutical/healthcare industry is under increasing shareholder pressure to get new
therapeutics to market, faster. Virtually every large pharmaceutical company has dedicated additional resources to
adding later-stage products to their pipeline. Hopen has positioned itself to bridge the development gap and
maximize products’ market potential.
In 2006 Hopen entered into partnership with Metabolic Solutions Development Company (MSD)
to develop innovative compounds addressing the growing global threat of type 2 diabetes. Using Hopen’s resource
network, MSDC spent less than a year developing a pre-clinical package and filing an IND (investigational new drug)
application – all at costs well below industry averages. This successful endeavor has validated Hopen’s product
development methodology.
Hopen is in the screening phase with other investments and continues to explore new opportunities.
|
| |
|
|
Mark Olesnavage, MBA
President
|
Douglas Morton, PhD
|
David Van Andel
CEO and Chairman, Van Andel Institute
|
| |
|
|
Jerry Callahan, PhD, MBA, MS
Chief Operating Officer
|
William Baer, MD, PharmD
|
Hon. William Nicholson
CEO, IdeaSphere Inc.
|
| |
|
|
Paul Simon, RPh
Vice President, Development
|
W. Gary Tarpley, PhD
|
Mike Jandernoa
Former CEO and Chairman, Perrigo Company
Principal/Partner, Bridge Street Capital
|
| |
|
|
Michelle Antunes, MBA
Operations Manager
|
Daniel Hartman, MD, FCCP
|
Mark Olesnavage
President, Hopen Therapeutics, LLC
|
| |
|
|
|
Biographies...
|
Biographies...
|
Jerry Callahan
COO, Hopen Therapeutics, LLC
|
| |
|
|
|
|
|
|